Opus Genetics, INC DEF 14A proxy statements

Opus Genetics, Inc. is calling its 2026 Annual Meeting of Stockholders to vote on key proposals including the election of directors, executive compensation, and a significant increase in authorized common stock to support future growth and financing needs.

Opus Genetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Opus Genetics will hold its annual meeting of stockholders virtually on April 30, 2025, to vote on director elections, auditor ratification, executive compensation, preferred stock conversion, and meeting adjournment.

Opus Genetics updates its proxy statement after the Sooch Group withdraws its director nominees for the upcoming annual meeting.

Opus Genetics files its definitive proxy statement and urges stockholders to vote for its board nominees, highlighting the company's transformation and progress while criticizing a campaign by former CEO Mina Sooch to replace a majority of directors.

Opus Genetics is urging shareholders to vote for its director nominees amidst a proxy fight initiated by a stockholder group led by former CEO Mina Sooch.

Ocuphire Pharma has issued a supplement to its proxy statement, updating the voting standard for a proposal to increase the number of authorized common shares from 75 million to 125 million, in light of a recent amendment to Delaware General Corporation Law.

Ocuphire Pharma, Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

Ocuphire Pharma is holding its annual stockholder meeting on June 11, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, stock issuance, and charter amendments.